NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.
An imipenem-resistant Enterobacter cloacae isolate was recovered from the blood of a patient with a hematologic malignancy. Analytical isoelectric focusing, inhibitor studies, hydrolysis, induction assays, and molecular sequencing methods confirmed the presence of a NmcA carbapenem-hydrolyzing enzyme. This first report of NmcA detected in North America warrants further investigation into its distribution and clinical impact.
Pottumarthy
Sudha
S
University of Washington School of Medicine, Seattle, Washington, USA.
Moland
Ellen Smith
ES
Juretschko
Stefan
S
Swanzy
Susan R
SR
Thomson
Kenneth S
KS
Fritsche
Thomas R
TR
D000328:Adult; D001426:Bacterial Proteins; D004352:Drug Resistance, Microbial; D016972:Enterobacter cloacae / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D007525:Isoelectric Focusing; D007951:Leukemia, Myeloid / Q000201:enzymology*; D008297:Male; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000235:genetics* / Q000302:isolation & purification
D001426:Bacterial Proteins; D015378:Imipenem; C088657:NmcA protein, Enterobacter cloacae; D001618:beta-Lactamases